Patients and alemtuzumab doses per regimen
| Single agent/Regimen . | No. of patients . | Alemtuzumab, no. doses/month . | Maximum doses . |
|---|---|---|---|
| MRD | 3 | 12 | 12 |
| Therapy | 2 | 12 | 36 |
| + Rituximab | 2 | 12 | 12 |
| + Pentostatin | 6 | 12 | 36 |
| + FCR | 23 | 3 | 18 |
| + Hyper CVAD | 3 | 3 | 9 |
| + MTX/asparaginase | 1 | 1 | 4 |
| Single agent/Regimen . | No. of patients . | Alemtuzumab, no. doses/month . | Maximum doses . |
|---|---|---|---|
| MRD | 3 | 12 | 12 |
| Therapy | 2 | 12 | 36 |
| + Rituximab | 2 | 12 | 12 |
| + Pentostatin | 6 | 12 | 36 |
| + FCR | 23 | 3 | 18 |
| + Hyper CVAD | 3 | 3 | 9 |
| + MTX/asparaginase | 1 | 1 | 4 |
MRD indicates minimal residual disease; FCR, fludarabine, cyclophosphamide, rituximab; CVAD, fractionated cyclophosphamide, vincristine, cytarabine, and dexamethasone; MTX, methotrexate.